moxifloxacin has been researched along with granisetron in 12 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (granisetron) | Trials (granisetron) | Recent Studies (post-2010) (granisetron) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 59 | 0 | 16 |
| 3,157 | 552 | 1,690 | 1,149 | 466 | 243 |
| Protein | Taxonomy | moxifloxacin (IC50) | granisetron (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 4.3 | |
| D | Rattus norvegicus (Norway rat) | 3.8019 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.8019 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.8019 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.8019 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 3.8019 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 1.76 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.7702 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 5 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 1.76 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baum, C; Bello, CL; Dinolfo, M; Huang, X; Levine, S; Mulay, M; Patyna, S; Rosen, L; Toh, M; Van Vugt, A | 1 |
| Donachie, P; Howell, J; Mason, JW; Moon, TE; O'Mahony, B; Selness, DS | 1 |
1 review(s) available for moxifloxacin and granisetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for moxifloxacin and granisetron
| Article | Year |
|---|---|
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Aza Compounds; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Granisetron; Heart Ventricles; Humans; Indoles; Moxifloxacin; Neoplasms; Placebos; Protein-Tyrosine Kinases; Pyrroles; Quinolines; Risk; Sunitinib; Time Factors | 2009 |
Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.
Topics: Administration, Cutaneous; Adolescent; Adult; Aza Compounds; Electrocardiography; Female; Fluoroquinolones; Granisetron; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Myocardial Contraction; Quinolines; Serotonin 5-HT3 Receptor Antagonists; Single-Blind Method; Young Adult | 2012 |
9 other study(ies) available for moxifloxacin and granisetron
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |